The 5 Most Interesting Analyst Questions From PacBio's Q1 Earnings Call

PacBio’s first quarter of 2025 was shaped by ongoing funding constraints in the academic and research sector, as well as continued uncertainty in global capital equipment spending. Management pointed to declining instrument sales—particularly Revio system placements—as a direct consequence of weaker academic budgets, especially in the United States. CEO Christian Henry highlighted that, “The Academic and Research Institute segment represented the lowest percentage of instrument shipments since the Revio launch,” underscoring the pressure on capital purchases. At the same time, the company’s consumable revenues reached new highs, driven by strong utilization and sustained demand from existing customers, which helped partially offset lower instrument sales.

Is now the time to buy PACB? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions PacBio’s Q1 Earnings Call

• Matthew Sykes (Goldman Sachs) asked how much the clinical opportunity could offset weak academic and government funding. CEO Christian Henry said expanding clinical diagnostics and rare disease applications are core to PacBio’s growth strategy and offer more durable revenue.
• Jack Meehan (Nephron Research) inquired about expected Revio and Vega placements and whether the short-read asset could be monetized. Henry confirmed Revio shipments are expected to decline, but Vega placements should grow, and PacBio is evaluating strategic alternatives for the short-read platform.
• Alex (for Kyle Mikson, Canaccord Genuity) questioned the rationale behind pausing development of the high-throughput short-read sequencer. Henry cited macroeconomic challenges, resource prioritization, and rapid advances in long-read technology as key factors in the decision.
• Harrison (for Mason Carrico, Stephens) asked about visibility into the Vega sales funnel. CFO Jim Gibson explained that lower-cost instruments enable better sales pipeline visibility, but noted ongoing risks related to tariffs and global demand.
• William Ruby (for Dan Brennan, TD Cowen) requested details on EMEA demand trends and the path to cash flow positivity. Henry highlighted EMEA’s strength in rare disease markets and emphasized that top-line growth, gross margin expansion, and disciplined spending are essential to achieve cash flow breakeven by 2027.

Catalysts in Upcoming Quarters

Over the coming quarters, the StockStory team will be watching (1) the pace of clinical market adoption, particularly for HiFi sequencing in hospitals and genetic testing labs, (2) the impact of restructuring on operating expenses and cash burn, and (3) any shifts in global trade policy or NIH funding that could affect instrument sales. Progress on new product rollouts and cost-saving initiatives will also be critical to track.

PacBio currently trades at $1.31, up from $1.19 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.